Nightingale Reports Strong Third Quarter Fiscal 2012 Results

Major contract win and acquisition drive 118% increase in Adjusted EBITDA and provide predictability for sustainable revenue growth and EBITDA margin expansion going forward

MARKHAM, ON, Feb. 28, 2012 /CNW/ - Nightingale Informatix Corporation ("Nightingale" or the "Company") (TSX-V: NGH), an application service provider (ASP) of electronic medical record (EMR) software and related services, announces its financial results for the three and nine months ended December 31, 2011. All results are reported under IFRS and are in Canadian dollars unless otherwise stated.

Q3 Fiscal 2012 Financial and Operational Summary

  • Revenue was $5.1 million, up 16% from $4.4 million in Q3 F2011, reflecting a significant increase in software revenue.
    • Total software revenue (EMR and Practice Management) was $4.7 million, up 27% from $3.7 million in Q3 F2011.

  • Gross profit was $4.3 million (or 85% of revenue) up from $3.6 million (81% of revenue) in Q3 F2011.

  • Operating Expenses, excluding stock based compensation, depreciation, amortization and one-time business acquisition, integration and other costs were $3.5 million compared to $3.2 million in Q3 F2011.

  • Adjusted EBITDA1 was $0.9 million (17% of revenue), up 118% from $0.4 million (9% of revenue) in Q3 F2011.

  • Net income was $0.4 million excluding one-time business acquisition, integration and other costs and a one-time write-off to interest expense, compared to $(0.2) million in Q3 F2011.

  • Cash from operations was $0.3 million compared to $0.6 million in Q3 F2011.

  • Total deferred revenue was $7.8 million, up from $7.5 million as at March 31, 2011.

  • In addition to signing agreements with healthcare providers to deploy 150 EMR seats2, won a contract with the Association of Ontario Health Centres (AOHC) to provide Nightingale on Demand EMR to cover 3,500 healthcare providers across Ontario over a two-year deployment, representing $9.0 million in revenue over the first three years, and up to $17.0 million over 10-year life of the contract. Company signed agreements to deploy approximately 220 seats in Q3 F2011.

  • Acquired assets of the Medrium Practice Management software business for US $1.7 million on December 19, 2011.  The Medrium software business is expected to add approximately $2.0 million of recurring revenue on an annual basis.

  • Subsequent to quarter end, appointed Marc Filion to the Company's Board of Directors.

"We hit an inflection point in Q3, with our significant increase in revenue, which was up 16% year-over-year and 25% sequentially, driving a substantial improvement in Adjusted EBITDA for the quarter," said Sam Chebib, President and CEO of Nightingale. "We signed one of the largest EMR contracts ever awarded in Canada and completed an acquisition that strengthens our presence in the U.S. and Quebec EMR markets. Given the transparency and predictability these transformational events provide for our financial results, we are confident our growth will continue over the coming quarters. In addition, we plan to stay disciplined with our expenses. As a result, we expect revenue improvements to materially outpace any increase in expenses, fueling further EBITDA margin expansion going forward."

Mr. Chebib continued: "EMR is our key growth driver, and we are seeing the market open up. Large enterprises along with small and medium-sized clinics are increasingly recognizing the value, technology leadership and cost efficiencies of a cloud-based EMR offering. We have a web-native solution, and are a leading EMR provider in Canada. We continue to gain market share, and with our plans to expand into Quebec, strengthen our position in the U.S. and augment our organic growth initiatives with strategic acquisitions where appropriate, we are well positioned to deliver continued long-term growth."

Fiscal 2012 Third Quarter and Year to Date (YTD) Financial Review 
Nightingale's Q3 and YTD fiscal 2012 results are prepared in accordance with IFRS. For more detailed information regarding the Company's transition to IFRS, including a reconciliation of the Company's Q3 fiscal 2011 YTD results as originally reported in Canadian Generally Accepted Accounting Principles (CGAAP) to IFRS please refer to the Company's financial statements and MD&A filings on SEDAR at www.sedar.com.

Revenue for Q3 fiscal 2012 was $5.1 million, up 16% from $4.4 million for Q3 fiscal 2011.  The year-over-year improvement was driven by a 27% increase in software revenue ($4.7 million for Q3 fiscal 2012, compared to $3.7 million in Q3 fiscal 2011) which was predominantly a result of the Company's major EMR contract win with the AOHC, as the Company recognized part of the revenue related to the contract in Q3 with the remainder of the revenue to be recognized over coming quarters. The Company generated 37% of Q3 fiscal 2012 revenue in US dollars.  However, foreign exchange fluctuations had a negligible impact on revenue for the quarter compared to the year ago quarter. YTD fiscal 2012 revenue was $12.7 million, down 2% from $13.0 million for the same period in fiscal 2011, due to slower enterprise sales in the first half of the fiscal year. The Company generated 40% of YTD fiscal 2012 revenue in US dollars. As a result, foreign exchange fluctuations had a $(0.2) million impact on revenue for the period. Foreign exchange fluctuations predominantly impact the Company's recurring revenue results.

Recurring revenue3 for Q3 fiscal 2012 was $2.5 million (49% of revenue), down in comparison to $2.7 million (60% of revenue) for Q3 fiscal 2011. YTD fiscal 2012 recurring revenue was $7.3 million (57% of revenue), down in comparison to $8.2 million (63% of revenue) for YTD fiscal 2011. These decreases were predominantly a result of a reduction in Revenue Cycle Management revenue, as the Company moves away from providing healthcare services to increasingly focus on being a leading technology provider.

Non-recurring revenue3 for Q3 fiscal 2012 was $2.6 million, up 50% from $1.7 million for Q3 fiscal 2011, largely reflecting revenue related to the Company's significant EMR contract with the AOHC. YTD non-recurring revenue for fiscal 2012 was $5.4 million, up 13% from $4.8 million for YTD fiscal 2011.

For Q3 fiscal 2012, gross margin was 85% ($4.3 million gross profit) compared to 81% ($3.6 million gross profit) for Q3 fiscal 2011. For YTD fiscal 2012, gross margin was 83% ($10.5 million gross profit) compared to 80% ($10.4 million gross profit) for YTD fiscal 2011.

Operating expenses for Q3 fiscal 2012, were $4.0 million, excluding charges for stock based compensation and depreciation and amortization, or $3.5 million also excluding one-time business acquisition, integration and other costs. This is compared to operating expenses of $3.2 million, excluding charges for stock based compensation and depreciation and amortization for Q3 fiscal 2011. YTD fiscal 2012 operating expenses were $10.0 million, excluding charges for stock based compensation and depreciation and amortization, or $9.5 million also excluding one-time business acquisition, integration and other costs. This is compared to $9.0 million in operating expenses, excluding charges for stock based compensation and depreciation and amortization for YTD fiscal 2011.

For Q3 fiscal 2012, adjusted EBITDA was $0.9 million, up 118% from $0.4 million in Q3 fiscal 2011. For YTD fiscal 2012, adjusted EBITDA was $1.0 million compared to $1.4 million for YTD fiscal 2011.

For Q3 fiscal 2012, net income was $(0.2) million, or $0.4 million excluding one-time business acquisition, integration and other costs and a one-time write-off to interest expense. This is compared to $(0.2) million in Q3 fiscal 2011. Net income for YTD fiscal 2012 was $(0.9) million, or $(0.4) million excluding one-time costs and one-time write-off, compared to $(0.7) million for YTD fiscal 2011.

Cash and cash equivalents were $3.0 million at December 31, 2011, down from $4.2 million at March 31, 2011, primarily as a result of the Company's increased investments in its long-term strategic growth initiatives.

At December 31, 2011, total common shares issued and outstanding were 76,310,915.

The financial statements and MD&A will be available at www.nightingalemd.com and filed on www.sedar.com on February 28, 2012.  This press release should be read in conjunction with Nightingale's Consolidated Financial Statements for the three and nine months ended December 31, 2011 and the accompanying Management Discussion and Analysis.

Notice of Conference Call
Nightingale will host a conference call on Tuesday, February 28, 2012, at 8:30 a.m. Eastern Standard Time. To access the conference call by telephone, dial (888) 231-8191 (or (647) 427-7450 for international). Please connect approximately fifteen minutes prior to the call, and reference conference ID 54208352 prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Tuesday, March 6, 2012. To access the archived conference call, dial 416-849-0833 or 1-855-859-2056 and enter reference 54208352 #. To listen to the conference call replay on the internet please visit the Nightingale website shortly after the call at www.nightingalemd.com.

Non-GAAP Financial Measures
The Company internally measures its performance and results of initiatives through a number of measures that are not recognized under Canadian generally accepted accounting principles (GAAP) and may not be comparable to similar measures used by other companies.

1. Adjusted EBITDA
Adjusted EBITDA is a non-GAAP measure that management believes is a useful measurement to evaluate the performance of the Company. Investors should be cautioned, however, that Adjusted EBITDA should not be construed as an alternative to net earnings as determined in accordance with GAAP. The Company's method of calculating Adjusted EBITDA may differ from the methods used by other companies and, accordingly, it may not be comparable to similarly titled measures used by other companies.

Adjusted EBITDA is defined as earnings before other loss (income), interest, income taxes, depreciation, amortization, stock-based compensation, and business acquisition, integration and other costs. Management believes it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance, and Management uses this information internally for forecasting and budgeting purposes.

The following provides a reconciliation of Adjusted EBITDA to Loss and Comprehensive Loss (dollars are in thousands):

                         
      Three Months
Ended
    Three Months
Ended
    Nine Months
Ended
    Nine Months
Ended
Definition     December 31,
2011
    December 31,
2010
    December 31,
2011
    December 31,
2010
                         
Loss and Comprehensive Loss   $ (190,655)   $ (245,478)   $ (942,780)   $ (668,283)
                         
Adjustments for:                        
Current Tax Expense (Benefit)   $ 12,212   $ -   $ 6,482   $ (10,520)
Other Loss (Income)     8,153     620     (4,554)     (14,570)
Interest     150,130     124,192     358,262     523,572
Depreciation and Amortization     376,816     474,247     1,008,356     1,313,101
Stock-based Compensation     32,777     50,140     95,989     262,611
Acquisition, Integration and Other     491,258     -     512,889     -
Adjusted EBITDA   $ 880,691   $ 403,721   $ 1,034,644   $ 1,405,911

2. Seat Sale
"Seat" is defined as a paying healthcare provider using Nightingale's Electronic Medical Record.

3. Recurring and Non-Recurring Revenue
The Company has included recurring revenue and non-recurring revenue measurements since it believes that this information is useful to investors to evaluate its performance. Investors should be cautioned, however, that recurring revenue and non-recurring revenue should not be construed as an alternative to revenue as determined in accordance with GAAP.  Recurring Revenue is comprised of utilization fees, hosting, support and maintenance revenue, data management and transcription services, billing and financial management services and transactional fees.  Non-Recurring Revenue is comprised of revenues generated from sales of software and systems and related training, data conversion and installation services.

The following provides a reconciliation of Recurring Revenue and Non-Recurring Revenue to Revenue (dollars are in thousands):

                         
      Three Months
Ended
    Three Months
Ended
    Nine Months
Ended
    Nine Months
Ended
Definition     December 31,
2011
    December 31,
2010
    December 31,
2011
    December 31,
2010
Non-Recurring Revenue   $ 2,620,072   $ 1,744,438   $ 5,401,754   $ 4,793,598
Recurring Revenue     2,472,624     2,660,887     7,302,873     8,227,068
                         
Revenue   $ 5,092,696   $ 4,405,325   $ 12,704,627   $ 13,020,666

About Nightingale
Nightingale is one of the fastest growing health care service and software companies in North America and is recognized as an industry leader in Web-based clinician and community based electronic medical records (EMR) serving the needs of small primary care practices, multi-physician outpatient clinics, and large scale regional health organizations and networks. Coupled with integrated practice management, transcription and revenue cycle management, Nightingale's comprehensive service offering allows customers to enhance patient care, increase revenue opportunities and optimize operations. Nightingale is continuously innovating and enhancing its services to meet the needs of its growing and diverse customer base. Nightingale - Healthcare connected. www.nightingalemd.com

Forward Looking Statement
This press release contains "forward-looking statements" respecting the issuance and cancellation of securities of the Company within the meaning of applicable Canadian securities legislation. Generally, forward-looking statements can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect",  "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may" ,"could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Nightingale to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the speculative nature of the medical software industry, which is affected by numerous factors beyond Nightingale's control; the ability of Nightingale to successfully secure customer contracts and the timing of securing such contracts; the ability of Nightingale to complete and successfully integrate its acquisitions on an accretive basis, Nightingale's access to debt and capital facilities, including compliance with current debt arrangements; the existence of present and possible future government regulation; the significant competition that exists in the medical software industry; the early stage of Nightingale's business, and risks associated with early stage companies, including uncertainty of revenues, markets and profitability and the need to raise additional funding.  All material assumptions used in making forward-looking statements are based on management's knowledge of current business conditions and expectations of future business conditions and trends. Certain material factors or assumptions applied by management in making forward-looking statements, include without limitation, factors and assumptions regarding future trends in healthcare spending, economic conditions affecting Nightingale and North American economies; Nightingale's ability to continue to fund its business, rates of customer defaults, relationships with, and payments to lenders, as well as Nightingale's operating cost structure.

Although Nightingale has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Nightingale does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws. Further information on Nightingale Informatix Corporation is available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2011

                         
      Three Months
Ended
    Three Months
Ended
    Nine Months
Ended
    Nine Months
Ended
                         
      December 31,
2011
    December 31,
2010
    December 31,
2011
    December 31,
2010
                         
                         
Revenue   $ 5,092,696   $ 4,405,325   $ 12,704,627   $ 13,020,666
                         
Cost of sales           744,254     839,788     2,193,850     2,594,509
                         
Gross profit         4,348,442     3,565,537     10,510,777     10,426,157
                         
Expenses                        
General and administration     967,856     822,336     2,480,839     2,423,109
Sales and marketing     797,378     818,228     2,314,624     2,409,680
Research and development     1,025,006     1,001,221     2,655,974     2,720,219
Client services     1,087,104     1,044,418     3,129,041     3,042,950
Business acquisition, integration and other costs     491,258     -     512,889     -
      4,368,602     3,686,203     11,093,367     10,595,958
                         
Operating income (loss)     (20,160)     (120,666)     (582,590)     (169,801)
                         
Interest     150,130     124,192     358,262     523,572
Foreign currency gain     8,153     620     (4,554)     (14,570)
                         
Loss before tax       (178,443)     (245,478)     (936,298)     (678,803)
Current tax expense (benefit)     12,212                           -                      6,482     (10,520)
                         
Loss and comprehensive loss   $ (190,655)   $ (245,478)   $ (942,780)   $ (668,283)
                         
Basic and diluted loss per common share                        
Loss and comprehensive loss per common share   $ (0.00)   $ (0.00)   $ (0.01)   $ (0.01)
                         
Weighted average number of common shares     76,310,915     76,310,915     76,310,915     75,649,594
                         
                         

CONSOLIDATED BALANCE SHEET
AS AT DECEMBER 31, 2011

             
      December 31, 2011     March 31, 2011
             
ASSETS            
             
Current assets            
Cash and cash equivalents   $ 2,951,523   $ 4,165,406
Accounts receivable     3,228,519     3,006,073
Other receivables     84,667     66,868
Inventory     6,056     19,882
Prepaid expenses     533,411     418,072
      6,804,176     7,676,301
             
Long-term assets            
Deferred costs     188,560     198,401
Property and equipment     457,647     573,928
Intangible assets     5,740,242     3,273,672
Goodwill     4,792,399     4,692,399
      11,178,848     8,738,400
             
Total assets   $ 17,983,024   $ 16,414,701
             
LIABILITIES            
             
Current liabilities            
Line of credit   $ 850,000   $ 950,000
Accounts payable and accrued liabilities   $ 2,665,389   $ 2,323,880
Current portion of deferred revenue            4,925,052            4,778,811
Current portion of finance lease obligations               94,440               145,437
Current portion of term loan     890,925     800,000
             9,425,806     8,998,128
             
Long term liabilities            
Term loan     2,566,595     767,857
Convertible debentures     1,901,677     1,820,050
Deferred revenue            2,871,560            2,731,075
Finance lease obligations               62,074               128,130
Income taxes payable     700,350     667,708
             8,102,256     6,114,820
             
Total liabilities         17,528,062         15,112,948
             
SHAREHOLDERS' EQUITY            
Capital stock     29,629,683         29,629,683
Contributed surplus           4,791,642           4,695,653
Equity portion of convertible debentures     269,880     269,880
Warrants              701,452              701,452
Deficit     (34,937,695)     (33,994,915)
      454,962               1,301,753
             
Total liabilities and shareholders' equity   $ 17,983,024   $ 16,414,701
             
             

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2011

                       
    Three months     Three months     Nine months     Nine months
    Ended     Ended     Ended     Ended
    Dec 31, 2011     Dec 31, 2010     Dec 31, 2011     Dec 31, 2010
                       
Cash flow from operating activities                      
Loss from operations $ (190,655)   $ (245,478)    $ (942,780)   $ (668,283)
                       
Adjustments for:                      
Depreciation and amortization   376,816     474,247     1,008,358     1,313,101
Amortization of transaction costs related to debt financing          84,177                (2,304)     111,074                41,433
Stock based compensation          32,777                50,140     95,989                262,611
Unrealized foreign exchange (gain) loss           (67,282)               (40,767)     82,050              60,837
Provision for bad debt   28,038     -     28,038     -
Interest accretion          23,121            23,121     69,363            39,537
           286,992     258,959     452,092     1,049,236
                       
Changes in non-cash working capital balances                      
Accounts receivable          (566,815)     (567,533)     (282,366)     (631,757)
Prepaid expenses         151,891     79,327     (106,207)     (16,278)
Inventory          (1,857)                  1,948     13,826             9,221
Deferred costs          36,018                  (63,452)     9,841               (54,255)
Other receivables          (74,408)     26,204     (17,634)     85,805
Accounts payable and accrued liabilities   255,604     32,260     228,347     (176,208)
Income taxes payable   (21,485)     25,824     32,642     53,049
Deferred revenue          189,209     778,477     286,726     1,548,566
Cash flows provided by operating activities   255,149     572,014     617,267     1,867,379
                       
Cash flow from investing activities                      
Purchase of property and equipment   (124,568)     (16,768)     (151,736)     (86,083)
Capitalized development costs          (423,169)               (84,054)     (1,418,234)            (563,835)
Acquisition of assets and liabilities from Medrium   (1,761,880)     -     (1,761,880)     -
Cash flows used in investing activities         (2,309,617)     (100,822)     (3,331,850)     (649,918)
                       
Cash flow from financing activities                      
Proceeds from line of credit borrowing   1,350,000     -     2,985,000     -
Repayment of line of credit borrowing   (1,175,000)     (840,000)     (3,085,000)     -
Proceeds from issuance of common shares, net of costs          -     -     -     1,243,119
Proceeds from convertible debt financing (net of costs)   -     -     -     2,017,373
Proceeds from term loan (net of costs)   3,457,520     -     3,457,520     -
Repayment of term loan          (1,266,667)     (133,333)     (1,666,667)     -
Repayment of subordinated debt financing   -     -     -     (3,529,910)
Repayment of finance lease obligations          (43,501)     (100,020)     (207,193)     (240,079)
Cash flows provided by (used in) financing activities          2,322,352     (1,073,353)     1,483,660            (509,497)
                       
Foreign exchange gains (losses) on cash in foreign currency         (7,515)     (11,643)     17,040     (92,460)
                       
Net increase (decrease) in cash          260,369     (613,804)     (1,213,883)                615,504
Cash and cash equivalents, beginning of period   2,691,154           3,027,555               4,165,406          1,798,247
                       
Cash and cash equivalents, end of period   $    2,951,523     $    2,413,751     $  2,951,523     $    2,413,751
                       
                       

OVERALL PERFORMANCE, RESULTS OF OPERATIONS AND FINANCIAL CONDITION

QUARTERLY DATA

                                             
    CGAAP
(1)
  CGAAP
(1)
  CGAAP
(1)
  IFRS   IFRS   IFRS   IFRS   IFRS   IFRS   IFRS   IFRS
    Q3   Q4   Fiscal
Year
  Q1   Q2   Q3   Q4   Fiscal
Year
  Q1   Q2   Q3
    Ended   Ended   Ended   Ended   Ended   Ended   Ended   Ended   Ended   Ended   Ended
 In $ 000's
  (Except per
Share Amounts)
  Dec 31,
 2009 
  March 31,
2010 
  March 31,
2010 
  June 30,
2010 
  Sept 30,
2010 
  Dec 31,
2010 
  March 31,
2011 
  March 31,
2011 
  June 30,
2011 
  Sept 30,
2011 
  Dec 31,
2011 
                                             
Recurring Revenue   $3,342   $2,849   $13,096   $2,843   $2,723   $2,661   $2,452   $10,679   $2,463   $2,367   $2,473
                                             
Non-Recurring Revenue   1,010   1,324   3,485   1,559   1,491   1,744   1,901   6,695   1,342   1,439   2,620
                                             
Revenue   4,352   4,173   16,581   4,402   4,214   4,405   4,353   17,374   3,805   3,807   5,093
Gross Profit   3,314   3,169   12,238   3,533   3,327   3,565   3,737   14,162   3,163   2,999   4,348
Expenses   3,384   3,474   13,693   3,357   3,553   3,686   3,870   14,466   3,500   3,225   4,369
Adjusted
EBITDA (Loss) (non-GAAP measure)
  593   406   1,203   616   386   404   445   1,851   23   131   881
                                             
Operating Income (Loss) for the Period   (70)   (306)   (1,455)   176   (225)   (121)   (135)   (304)   (337)   (225)   (20)
                                             
Loss and Comprehensive Loss   (350)   (1,524)   (3,444)   -   (422)   (245)   (205)   (874)   (437)   (315)   (191)
                                             
Loss and Comprehensive Loss per Common Share   $(0.00)   $(0.02)   $(0.05)   $(0.00)   $(0.01)   $(0.00)   $(0.00)   $(0.01)   $(0.00)   $(0.00)   $(0.00)
                                             
Weighted Avg. # of Common Shares   70,535   70,535   70,232   72,809   76,311   76,311   76,311   75,979   76,311   76,311   76,311
Total Assets   $14,714   $14,651   $14,651   $16,873   $15,744   $15,218   $16,415   $16,415   $15,521   $15,267   $17,983
                                             
Total Long-Term
Liabilities
  $7,062   $7,918   $7,918   $1,979   $5,185   $5,337   $6,115   $6,115   $5,819   $5,972   $8,102
                                             
Total Deferred Revenue   $4,928   $5,239   $5,239   $5,805   $6,010   $6,788   $7,510   $7,510   $7,588   $7,607   $7,797

(1) Financial information in this table for periods prior to April 1, 2010 have not been restated for changes in accounting policies on adoption of IFRS. Refer to the Company's MD&A filed on SEDAR at www.sedar.com for a discussion of IFRS and its impact on the Company's financial statements.

 

 

 

 

SOURCE Nightingale Informatix Corporation

For further information:

Michael Ford, CFO
Nightingale Informatix Corporation
Tel: 905-307-7870
mford@nightingalemd.com 

Kristen Dickson, Account Executive
The Equicom Group
Tel: 416-815-0700 ext. 273
kdickson@equicomgroup.com

Profil de l'entreprise

Nightingale Informatix Corporation

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.